Trials / Completed
CompletedNCT02233244
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
A Phase 1, Open-Label, Two-Period, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Celtaxsys, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This drug-drug interaction study will assess the potential of CTX-4430 to induce CYP3A activity in healthy subjects. The study hypothesis is that midazolam (a sensitive, widely used CYP3A4 substrate) blood levels will not change after treatment with CTX-4430.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTX-4430 | |
| DRUG | Midazolam |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2014-09-08
- Last updated
- 2014-10-10
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02233244. Inclusion in this directory is not an endorsement.